Your browser doesn't support javascript.
loading
Next generation immunotherapy: enhancing stemness of polyclonal T cells to improve anti-tumor activity.
Kishton, Rigel J; Vodnala, Suman K; Vizcardo, Raul; Restifo, Nicholas P.
Afiliación
  • Kishton RJ; Lyell Immunopharma Inc., South San Francisco, CA, USA. Electronic address: rkishton@lyell.com.
  • Vodnala SK; Lyell Immunopharma Inc., South San Francisco, CA, USA.
  • Vizcardo R; Lyell Immunopharma Inc., South San Francisco, CA, USA.
  • Restifo NP; Lyell Immunopharma Inc., South San Francisco, CA, USA. Electronic address: nrestifo@lyell.com.
Curr Opin Immunol ; 74: 39-45, 2022 02.
Article en En | MEDLINE | ID: mdl-34710751
ABSTRACT
The administration of T cells as cellular therapy against advanced cancers has brought clinical benefit to many patients and has progressed the field of cancer research. However, current cell therapy treatments are not curative in most patients, particularly in those with solid tumors, and it remains to be seen how broadly and efficaciously they may be applied going forward. Recent research has begun to elucidate key factors that regulate the efficacy of cell therapy in cancer patients, including T cell stemness and the ability to effectively target tumor antigens and overcome tumor heterogeneity. In this review, we discuss key properties of clinically effective anti-cancer T cell therapies along with strategies to improve T cell characteristics to augment clinical efficacy in solid tumors.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfocitos T / Neoplasias Límite: Humans Idioma: En Revista: Curr Opin Immunol Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2022 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfocitos T / Neoplasias Límite: Humans Idioma: En Revista: Curr Opin Immunol Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2022 Tipo del documento: Article
...